EUCTR2006-005007-34-NL进行中（未招募）不适用
Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantation
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- MC
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female and at least 18 years-of-age
- •-MM patients with any type of relapse or progressive disease following (non) myeloablative allo-SCT for which DLI is considered a treatment option (including patients previously participating in Hovon 54 or Hovon 65 studies)
- •-Informed consent
- •-Haematological parameters; Hb > 4.0 mmol/L, leucocytes > 1.0×109/L , thrombocytes > 25 ×109/L, with or without transfusion
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-use of immunosuppressive drugs, for example cyclosporin, MMF, corticosteroids
- •-existing GvHD > grade A
- •-any non-hematological toxicity CTC grade = 3
- •-neuropathy CTC grade = 2
- •-pregnancy
- •-previous use of bortezomib is not an exclusion criterion, however patients refractory to bortezomib during previous treatment are excluded from this study
研究者
相似试验
招募中
2 期
Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantatiobone marrow cancerplasmacel dyscrasia10035227NL-OMON31757niversitair Medisch Centrum Utrecht20
进行中（未招募）
不适用
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsEUCTR2008-004822-17-NLniversity Medical Center
已完成
2 期
Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patientsM. Kahler.10018849Multiple myelomaNL-OMON38293niversitair Medisch Centrum Groningen73
已完成
不适用
Bortezomib (Velcade®) therapy combined with Donor Lymphocyte Infusion in patients with relapsed multiple myeloma following allogeneic stem cell transplantatioMultiple myelomaCancerISRCTN53810679niversity Medical Centre Utrecht (UMCU) (The Netherlands)20
进行中（未招募）
1 期
Induction therapy with bortezomib-melphalan and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide and dexamethasone plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 yearsMultiple myelomaEUCTR2017-000044-18-ESFundación PETHEMA462